Cardiovasculaire Geneeskunde.nl

Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, andWarfarin in Newly Diagnosed Atrial Fibrillation

Hernandez I, Zhang Y, Saba S. Am J Cardiol. 2017

28 sep. 2017

Hernandez I, Zhang Y, Saba S. Am J Cardiol. 2017

Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation

McHorney CA, Ashton V, Laliberté F et al., J Manag Care Spec Pharm. 2017

22 sep. 2017

McHorney CA, Ashton V, Laliberté F et al., J Manag Care Spec Pharm. 2017

Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation

Adeboyeje G, Sylwestrzak G, Barron JJ et al, J Manag Care Spec Pharm. 2017

20 sep. 2017

Adeboyeje G, Sylwestrzak G, Barron JJ et al, J Manag Care Spec Pharm. 2017

Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation - Systematic Review and Meta-Analysis

NOAC RWE studies

25 aug. 2017

Ntaios G, Papavasileiou V, Makaritsis K et al., Stroke. 2017

Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients

Deitelzweig S, Luo X, Gupta K et al., Curr Med Res Opin. 2017;33:1745-54

19 aug. 2017

Deitelzweig S, Luo X, Gupta K et al., Curr Med Res Opin. 2017;33:1745-54

Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer

Laube ES, Yu A, Gupta D, et al., Am J Cardiol 2017;120:213e217

8 aug. 2017

Laube ES, Yu A, Gupta D, et al., Am J Cardiol 2017;120:213e217

Veiligheid van NOAC-gebruik in de dagelijkse, Nederlandse klinische praktijk

10 juli 2017 - Pisters R et al., Neth Heart J. 2017

Analyse van NOAC gebruik en veiligheidsevents in Nederlandse AF-patiënten die rivaroxaban krijgen voor beroertepreventie, opgenomen in het XANTUS register.

Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies

Deitelzweig S, Farmer C, Luo X et al., Current Medical Research and Opinion 2017

9 juli 2017

Deitelzweig S et al., Current Medical Research and Opinion 2017

Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry

Helmert S, Marten S, Mizera H et al., J Thromb Thrombolysis. 2017 Jun 22. doi: 10.1007/s11239-017-1519-8.

23 juni 2017

Helmert S et al., J Thromb Thrombolysis. 2017

Non–Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction

Yao X, Shah ND, Sangaralingham LR et al., J Am Coll Cardiol. 69(23) 2017

17 juni 2017

Yao X et al., J Am Coll Cardiol. 2017

Wat kunnen de antistollingspolikliniek en de huisarts doen voor de AF-patiënt?

10 mei 2017 - Nijmegen - Dr. Marc Brouwer en Stijn van Vugt

Dr. Marc Brouwer en Stijn van Vugt geven een inkijkje in de werkwijze van de antistollingspolikliniek. Brouwer overweegt waar huisartsen aan moeten denken als zij een patiënt met AF zien.

Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis

Bai Y, Deng H, Shantsila A, Lip GY. Stroke. 2017

17 feb. 2017

Bai Y et al., Stroke. 2017